Sumitomo Chemical カジノシークレット やばい Sumitomo Dainippon Pharma Announce Establishment カジノシークレット やばい Inception of Operations of a Joint Venture Company for CDMO Business in the field of Regenerative Medicine カジノシークレット やばい Cell Therapy

Oct. 8, 2020

カジノシークレット やばい Chemical Co., Ltd.
カジノシークレット やばい Dainippon Pharma Co., Ltd.

Sumitomo Chemical Company Limited (Head Office: Chuo-ku, Tokyo, Japan; Representative Director カジノシークレット やばい President: Keiichi Iwata; “Sumitomo Chemical”) カジノシークレット やばい Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Chuo-ku, Osaka, Japan; Representative Director, President カジノシークレット やばい CEO: Hiroshi Nomura; “Sumitomo Dainippon Pharma”) announced today that, in September 2020, they had established S-RACMO Co., Ltd. (S-RACMO), a joint venture company to develop manufacturing methods カジノシークレット やばい manufacture products for the regenerative medicine カジノシークレット やばい cell therapy field. S-RACMO has started operations カジノシークレット やばい will undertake business as a Contract Development カジノシークレット やばい Manufacturing Organization (CDMO).

The establishment of manufacturing systems is a major issue faced by academia カジノシークレット やばい startups in the development カジノシークレット やばい commercialization of regenerative medicine カジノシークレット やばい cell therapy. Sumitomo Chemical カジノシークレット やばい Sumitomo Dainippon Pharma have decided to embark on the CDMO business to achieve the early diffusion カジノシークレット やばい commercialization of regenerative medicine カジノシークレット やばい cell therapy. They aim to leverage Sumitomo Chemical’s expertise in basic iPS/ES cell technologies カジノシークレット やばい pharmaceutical contract manufacturing カジノシークレット やばい Sumitomo Dainippon Pharma’s expertise gained by developing sophisticated manufacturing methods カジノシークレット やばい pharmaceutical development through multiple projects in the regenerative medicine カジノシークレット やばい cell therapy business.

The global market for CDMO business in the field of regenerative medicine カジノシークレット やばい cell therapy is expected to grow to around 1.2 trillion yen by 2030*. Leveraging group synergies, Sumitomo Chemical カジノシークレット やばい Sumitomo Dainippon Pharma will strive to gain a solid share in this market カジノシークレット やばい build up a higher level of technology カジノシークレット やばい expertise in CDMO operations. In addition, by moving into the CDMO business, Sumitomo Chemical aims to expカジノシークレット やばい its business in the life science area by increasing contract pharmaceutical manufacturing, building on its contract manufacturing business in small molecule カジノシークレット やばい nucleic acid therapeutics. Sumitomo Dainippon Pharma aims to diversify its business in the regenerative medicine カジノシークレット やばい cell therapy field so as to contribute more to earnings カジノシークレット やばい gain new opportunities for partnerships.

S-RAMCO will conduct CDMO business in some of a manufacturing facility for regenerative medicine カジノシークレット やばい cell therapy (SMaRT) owned by Sumitomo Dainippon Pharma カジノシークレット やばい a manufacturing facility for regenerative medicine カジノシークレット やばい cell therapy, which will be built on the premises of its Central Research Laboratories (Suita, Osaka) of Sumitomo Dainippon Pharma. In addition, Sumitomo Dainippon Pharma has already started negotiations with CorneaGen Inc. (Washington State, USA) to receive the contract to manufacture corneal endothelial cells (planned indication: corneal diseases) カジノシークレット やばい to develop its manufacturing method, so that S-RACMO can undertake this responsibility for CorneaGen in Japan.

*Investigated by Deloitte Tohmatsu Consulting LLC

Outline カジノシークレット やばい the joint venture company

Company name	S-RACMO Co., Ltd. S-RACMO is an acronym カジノシークレット やばいSumitomo カジノシークレット やばいRegenerativeAnd CellularMedicineOrganization.
Address	33-94 Enoki-cho, Suita, Osaka, Japan (on the premises of カジノシークレット やばい Dainippon Pharma’s Central Research Laboratories)
Representative Director カジノシークレット やばい President	Atsushi Tsuchida (Previously Senior Director, Research Planning & Coordination, Drug Research Division of カジノシークレット やばい Dainippon Pharma)
Lines カジノシークレット やばい business	CDMO of development of manufacturing methods カジノシークレット やばい manufacturing for regenerative medicine カジノシークレット やばい cell therapy field products.
Capital	￥50 million
Established on	September 1, 2020
Ownership structure	カジノシークレット やばい Dainippon Pharma 51%, カジノシークレット やばい Chemical 49%

Outline of the new regenerative カジノシークレット やばい cellular medicine manufacturing facility to be built

Address	33-94 Enoki-cho, Suita, Osaka, Japan (on the premises of カジノシークレット やばい Dainippon Pharma’s Central Research Laboratories)
Building size	1 story
Building area	approx. 600 m2
Start カジノシークレット やばい construction	January 2021(plan)
Completion	December 2021 (plan)
Total construction cost	approx. ￥1.1 billion

Reference

CorneaGen Inc.

CorneaGen Inc. provides ophthalmic surgeons カジノシークレット やばい their patients with innovations in cornea care that include new medical devices カジノシークレット やばい biologics, novel therapeutics カジノシークレット やばい interventions, surgeon education, カジノシークレット やばい advocacy for patient access カジノシークレット やばい reimbursement.

CorneaGen has acquired the rights to technologies related to corneal endothelial cell therapy, from Professor Shigeru Kinoshita of Department of Frontier Medical Science カジノシークレット やばい Technology for Ophthalmology, from Kyoto Prefectural University of Medicine, カジノシークレット やばい others. For details, please visit:https://corneagen.com

Contact